Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.

ABSTRACT: The therapeutic concept of unleashing a pre-existing immune response against the tumor by the application of immune-checkpoint inhibitors (ICI) has resulted in long-term survival in advanced cancer patient subgroups. However, the majority of patients do not benefit from single-agent ICI and therefore new combination strategies are eagerly necessitated. In addition to conventional chemotherapy, kinase inhibitors as well as tumor-specific vaccinations are extensively investigated in combination with ICI to augment therapy responses. An unprecedented clinical outcome with chimeric antigen receptor (CAR-)T cell therapy has led to the approval for relapsed/refractory diffuse large B cell lymphoma and B cell acute lymphoblastic leukemia whereas response rates in solid tumors are unsatisfactory.

SUBMITTER: Huemer F 

PROVIDER: S-EPMC7215892 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature